Emerging Technologies and a Sustainable, Healthy, Just World
By Marcy Darnovsky and Jesse Reynolds,
Biodiversity: The Newsletter of the Consultative Group on Biological Diversity (Winter 2010)
| 02. 24. 2010
The Case of Human Reproductive and Genetic Technologies
Synthetic biology is the rapidly developing field devoted to engineering life from the ground up. It has recently generated headlines about startling applications such as the effort to artificially construct a living bacterium, molecule by molecule. But one of its leading practitioners doesn’t think the engineering of life will stop there. Stanford’ University’s Drew Endy recently told The New Yorker:
“What if we could liberate ourselves from the tyranny of evolution by being able to design our own offspring? Think about what happens when you really can print the genome of your offspring. You could start with your own sequence, of course, and mash it up with your partner, or as many partners as you like.”
Synthetic biology is just one of a set of powerful emerging technologies challenging efforts toward environmental sustainability, human health, and social justice. The on-going controversies surrounding genetically-modified crops are just the beginning. Biotech companies are now deploying cloned and genetically modified farm animals.
Nanotechnology, or manufacturing at the atomic scale, proposes to remake the world “from the bottom-up” and simple forms of nanotechnology...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...